Introduction
Unlike Mycobacterium tuberculosis, nontuberculous mycobacteria (NTM) are ubiquitous organisms, present in the environment. The number of species of NTM is increasing every year. Previously considered contaminants of sputum, NTM are able to produce lung disease in humans. However, there are many gaps in the understanding of the pathogenesis and treatment of this heterogeneous group. The present review will focus on recent medical literature about NTM.
Epidemiology
Most epidemiologic studies of NTM have been performed in North America, Japan and Europe. In recent years, new information about the epidemiology of NTM in other parts of the world has appeared. Two small studies have been done in the Arabian Peninsula. In Oman, NTM were isolated from 4.6% of patients with mycobacteria isolation during a period of 6 months
[1]. The predominant NTM species was Mycobacterium fortuitum. In a reference hospital in Kuwait, the rate of NTM among mycobacteria isolations was higher (9%) [2] . Thirteen of these isolations were randomly identified and Mycobacterium avium complex (MAC) was the predominant species (69%).
In a district hospital in Zambia, patients with productive cough for more than 2 weeks were investigated for mycobacteria infection [3 ] . Of the 180 patients, NTM were isolated in 31 (17%) and four patients (2%) were considered to have NTM disease. M. tuberculosis was isolated in 72 patients (40%). A high proportion of not previously identified NTM (32%) were isolated although all cases of NTM disease were produced by MAC. Interestingly, NTM isolation was associated with the use of tap water. With the increasing use of tap water, in the future we will probably see an increase in the incidence of NTM diseases in developing countries with high prevalence of HIV infection. Identification of mycobacteria species is not readily available in these countries so patients with tuberculosis (TB)-like disease produced by NTM will not receive specific treatment for their condition.
In Asia, information about isolations of NTM from 1993 to 2006 was collected in a reference laboratory in South Korea [4] . During this period, 17 915 isolations of NTM were collected and it was observed that there was an increased number of isolations over time. The most common species was MAC followed by rapid growing mycobacteria (Mycobacterium abscessus, M. fortuitum and Mycobacterium chelonae). In contrast with previous studies done in Japan, the number of isolations of Mycobacterium kansasii was not so frequent although an upward trend was observed. Unfortunately, no clinical data were provided in this study.
A referral laboratory in Brazil performed a similar study from 1996 to 2005 [5] . Of the 1300 isolations of mycobacteria, 24.4% were NTM and again MAC was the predominant species.
Pathogenesis of nontuberculous mycobacteria disease
NTM are present in the environment and the way of transmission to humans is not well known. However, increasing data support that NTM infect human hosts through tap water [3 ,6] . Moreover, NTM are resistant to chemical disinfectants and ultraviolet irradiation used in water treatment processes [7] .
Virulence varies between NTM species [8 ] . Even within the same species, some strains are more virulent than others [9] [10] [11] . A group of Japanese investigators found a hypervirulent strain of Mycobacterium intracellulare from an immunocompetent patient with rapidly progressive lung disease [11] . This strain was highly resistant to human macrophages and produced rapid progressive lung disease in mice.
Information about risk factors of the host for NTM disease is confusing because data come from series of case reports and retrospective studies. Many factors have been involved in the increased susceptibility for NTM such as preexisting lung disease, immunosuppression or genetic defects of cell-mediated immunity [12] . To clarify this issue, a group of North American investigators performed a prospective study of 63 patients with NTM disease [13 ] . Radiological studies (computed tomography scan of thorax, chest radiograph and echocardiography), pulmonary function testing, clonal proliferation of T or B cells, stimulated cytokine production and flow cytometry of peripheral blood and anthropometric measurements were performed to the patients and compared with a control group. Patients with NTM lung disease were predominantly women, were taller and thinner and had more frequently scoliosis, pectum excavatum and mitral valve prolapse than the control group. No differences were seen in the immunological results whereas 36.5% of patients had some mutations of cystic fibrosis transmembrane conductance regulators. Voluntary factors such as cough suppression and shower exposure were not related to NTM disease. Authors conclude that NTM disease occurs in women with a characteristic phenotype probably secondary to an unknown genetic defect.
Studies involving specific nontuberculous mycobacteria species
Among rapid growing mycobacteria, M. fortuitum has low virulence. In a study done in Korea, of the 186 patients with M. fortuitum in sputum culture only 14% had repeated isolations and only one patient (0.5%) was considered to have lung disease produced by this mycobacteria [14 ] . For patients with at least two isolations, median follow up was 12.5 months and none of them showed clinical or radiological progression.
In one retrospective study in the Netherlands, Mycobacterium xenopi was isolated from 49 patients and 25 (51%) fulfilled the American Thoracic Society (ATS) diagnostic criteria [15, 16] . Twenty-one patients received treatment which consisted of medication for 17 patients, surgery for two and both for two. Four patients who met ATS criteria were not treated, one recovered spontaneously, one died and two remained positive for M. xenopi culture. Factors associated with fulfilment of ATS criteria were having positive acid-fast bacilli (AFB) in sputum smear and cavity on chest radiograph. In north-east France, the proportion of patients with M. xenopi isolation who met ATS criteria was higher (136 out of 180, 76%) [17 ] . The authors describe three different clinical and radiological patterns: cavitary form in patients with preexisting lung disease, nodulary form in immunocompetent patients and diffuse infiltrates in patients with HIV infection. As in other NTM studies, there was poor correlation between in-vitro sensitivities to antimycobacterial drugs and clinical response. In multivariate analysis, use of rifampicin was associated with increased survival. However, we have to be cautious in interpreting survival data from retrospective studies because many confounding factors can affect the results of the study. Patients with HIV, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD) or cystic fibrosis have different prognostic factors that should be taken into account when doing survival analysis. M. xenopi is the most common NTM isolated in Croatia [18] . In one retrospective study, of 40 patients with M. xenopi isolation, 24 (60%) met ATS diagnosis criteria [18] . Twenty patients received antimycobacterial treatment although for a shorter period than recommended [15] . No one experienced radiological progression, half improved and half experienced no improvement in symptoms and radiological changes. Having COPD was associated with no radiological improvement after treatment. Again, it is uncertain whether these outcomes are due to the underlying lung disease or to lack of response to treatment.
The biggest series of cases of Mycobacterium szulgai has been published recently by a group from the Netherlands [19 ] . Extrapulmonary infection was seen exclusively in five immunocompromised patients. Of the 15 patients with M. szulgai isolation from sputum, 11 (73%) fulfilled ATS diagnostic criteria and all had underlying lung disease. Three patients did not receive antimycobacterial treatment, one died, one refused treatment and one experienced spontaneous conversion to negative sputum culture. Treatment outcome was favourable as no patient suffered relapse.
Mycobacterium simiae seems to have low virulence in the Netherlands [20 ] . Of the 28 isolations, only six (21%) fulfilled ATS criteria and no extrapulmonary infection was seen. Moreover, two out of the three patients who met ATS criteria remained clinically stable despite not receiving antimycobacterial treatment. Treatment results were poor, with two relapses out of the three treated patients. Drug susceptibility testing of 25 samples showed in-vitro resistance to most antimycobacterial drugs but clofazimine, cycloserine and protionamide. In one series of 102 patients with repeated M. simiae isolation in Israel, comorbid diseases and involvement of middle and lower lobes in chest radiographs were common [21] . A small number of patients presented with pleural effusion and lymphadenitis.
As M. tuberculosis, M. kansasii produces infiltrates or cavities in the upper lobes in immunocompetent patients [21] . However, in one series of 83 patients with HIV infection, mid and lower zones of the lungs were involved in 89% of patients, most commonly in the form of consolidation or nodules [22] . Although less common, cavitation was associated with increased mortality. Treatment outcome of M. kansasii is generally good if treatment is given for at least 12 months. A Spanish study showed relapse in only 6.6% of patients [23] . No acquired drug resistance was seen and all patients responded to a longer course of treatment for 18 months.
M. abscessus is highly resistant to medical treatment both in vitro and in vivo. A group of Spanish microbiologists studied multiple combinations of antibiotics against two strains of M. abscessus in vitro [24] . Interestingly, clarithromycin with linezolid and clarithromycin with rifabutin and fluoroquinolones exhibited good activity. However, clinical trials are needed to confirm these results in vivo and surgery still remains as the main treatment for M. abscessus and other highly resistant NTM. Actually, if patients are selected carefully, resection of the lung area affected by NTM is usually effective [25 ] .
Isolation of nontuberculous mycobacteria
In places with low incidence of M. tuberculosis, it can be difficult to determine whether AFB smear positive sputum is produced by M. tuberculosis or NTM. Mycobacteria identification will not be known until at least a few weeks, leading to unnecessary isolation measures. A positive interferon-g release assay using specific M. tuberculosis antigens suggests TB infections rather than MAC disease [26] . A commercial direct amplification test has been recently developed to allow rapid identification of M. tuberculosis, Mycobacterium avium, M. intracellulare, M. kansasii and Mycobacterium malmoense [27 ] . Amplification was successful in 80-85% using three different approaches for specimen preparation. Results showed good specificity, as all identifications were concordant with cultures, but this assay had problems identifying MAC.
Up to 70% of M. xenopi isolations can be missed if nonradiometric and fully automated Bactec MGIT 960 system (Becton Dickinson Microbiology Systems, Sparks, Maryland, USA) is used, especially if bacterial load is low [28] . Some authors recommend checking for the presence of granules by visual inspection before discarding MGIT 960 tubes.
Diagnosis of nontuberculous mycobacteria lung disease
In clinical practice, when receiving a positive sputum culture for NTM it is difficult to know whether the isolation means contamination of sputum, transient colonization, chronic colonization or a true infection. The ATS has established clinical and microbiological criteria for the diagnosis of NTM lung disease [15] .
ATS criteria for diagnosing nontuberculous mycobacteria lung disease [15] :
(1) Clinical criteria:
(a) Pulmonary symptoms and radiological abnormalities (nodules or cavities on chest radiograph or multifocal bronchiectasis with multiple small nodules on high-resolution computed tomography scan). Other diagnoses must be excluded; (2) Microbiologic criteria (any of the following):
(a) Positive culture results from at least two separate sputum samples; (b) Positive culture results from at least one bronchial wash or lavage; (c) Lung biopsy with mycobacterial histopathologic features (granulomata or AFB) and positive Good response to treatment [19 ] M. xenopi
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Am, amikacin 25 mg/kg TIW (three times weekly) intravenous (i.v.; 10-15 mg/kg/day for severe disease); Azr, azithromycin 250 mg/day (500 mg/day for HIV infected patients); Cfx, ciprofloxacin, 500-750 mg bid; Clr, clarithromycin 800-1000 mg/ day; E, ethambutol 15 mg/kg/day; H, isoniazid 5 mg/kg/day (maximum 300 mg); Lfx, levofloxacin 500 mg/day; Mxf, moxifloxacin 400 mg/day; R, rifampicin 10 mg/kg/day (maximum 600 mg); Rb, rifabutin 5 mg/kg/day (maximum 300 mg); RGM, rapidly growing mycobacteria; S, streptomycin 25 mg/kg TIW intramuscular or i.v. (1 g/day for severe disease). Evidence-based classification, strength of recommendations: A, good; B, moderate; C, poor. Quality of evidence for recommendations: I, at least one randomized clinical trial; II, at least one not randomized clinical trial, cohort or case-control analytic studies or multiple time-series, or dramatic results in uncontrolled experiments; III, descriptive studies or opinions. Adapted from [15, 30] .
culture for nontuberculous mycobacteria from biopsy, bronchial wash or sputum.
Despite being a useful tool, these criteria are far from being adequate for all patients from whom NTM are isolated. ATS diagnostic criteria were designed for M. avium, M. kansasii and M. abscessus. However, more than 100 NTM species have been catalogued and not all NTM have the same level of virulence.
Most of the patients will meet clinical criteria as the majority will have pulmonary symptoms and radiological abnormalities are not specific for NTM. Only one positive culture from a bronchial specimen is needed to meet microbiological criteria because bronchial washing can avoid contamination of NTM from the mouth. Still, contamination of bronchoscopes has been described [29] . Repeated NTM positive sputum culture is very unlikely to occur in contaminations and only two separate positive sputum samples are needed to meet microbiological criteria. Nevertheless, patients with transient colonization will have negative sputum cultures after a period of time despite not receiving any antimycobacterial treatment [14 ,16,19 ,20 ] . Patients with preexisting lung cavity or bronchiectasis can be colonized by fungus or NTM and they will have persistent positive NTM cultures. These patients will meet ATS criteria but it is uncertain whether they would benefit from a long and expensive treatment with side effects and drug interactions [18] .
Basically, we can distinguish three main groups of human hosts, immunocompromised patients, healthy patients with nodulary-bronchiectatic form and patients with underlying lung disease. Isolation of NTM in sputum of immunocompromised patients may reflect a disseminated disease rather than localized lung disease [8 ] . ATS radiological criteria may not be fulfilled because up to 50% of patients will have normal chest radiograph [8 ] . In one Spanish study, the presence of AFB in sputum smear and symptoms for more than 1 month were useful indicators of NTM disease in HIV patients [8 ] . Not all species of NTM had the same clinical significance. All cases with M. xenopi isolation were considered as colonization and all cases with M. kansasii isolation were considered as true infection. In immunocompromised patients, isolation of NTM from a normally sterile site such as liver or bone marrow must be investigated, because this will give a definitive diagnosis of NTM disease.
NTM are a heterogeneous group that affects a wide range of human hosts with different characteristics, so it might be too optimistic to expect that a single set of diagnostic criteria would be accurate for all kind of patients. Probably, there are no correct universal criteria for deciding when to treat NTM as a whole. Decisions must be individualized. Immunocompromised patients with disseminated disease may have normal chest radiograph. Current ATS microbiologic criteria may be useful for virulent NTM, but more demanding criteria might be preferable for less virulent NTM. Patients with NTM disease have slowly progressive disease, so treatment of NTM is generally not urgent. The presence of AFB in sputum smear indicates high burden of mycobacteria and it is unlikely to happen in NTM contamination or colonization. Introducing a time-factor can be also useful. For example, three repeated isolations of NTM from sputum samples separated by 1 month will be rare in contamination or transient colonization. Moreover, in cases of NTM with low virulence, histopathologic features of mycobacterial infection such as granulomata or AFB in lung biopsy may be desirable for initiating treatment. Radiological criteria are difficult to interpret in patients with underlying lung disease or immunosuppression, but they can be specific for NTM in patients with nodularybronchiectatic lesions and no other comorbidities.
Treatment
Treatment of NTM with evidence-based classification is summarized in Table 1 [15,16,19 ,20 ,24,30,31] . In some cases of resistant NTM, surgical treatment is needed. In a referral hospital in South Korea, 23 patients underwent pulmonary resection because of resistant NTM infection [25 ] . One patient died because of late bronchopleural fistula, but there was no NTM relapse in the rest of the patients. However, postoperative complications occurred in 35% of patients, including postoperative pneumonia and late bronchopleural fistula. Authors concluded that despite high postoperative morbidity, resectional surgery is an effective treatment for those patients who can tolerate the operation and there has been poor response to medical treatment or life-threatening complications such as haemoptysis.
Conclusion
Recent findings indicate that NTM infection of the lungs is a worldwide phenomenon. NTM form a heterogeneous group with variable virulence among species. In patients without underlying lung disease or immunosuppression, factors related to host susceptibility are associated with a characteristic phenotype and defects on cystic fibrosis transmembrane conductance regulators. ATS diagnostic criteria are a useful tool but they may lead us to treat many patients unnecessarily. Factors such as the virulence of the NTM species and characteristics of the host should be taken into account when deciding whether to treat a patient with NTM isolation. However, more information about the pathogenesis and treatment of NTM is needed. Because NTM infections are rare, physicians and scientists should join efforts to perform Lung disease caused by nontuberculous mycobacteria Alvarez-Uria 255 multicentric prospective studies of specific species of NTM in the different groups of human hosts.
